2005). BiMuno™ has been shown to reduce colonisation of pathogenic Salmonella

76
Typhimurium in mice by Searle et al (Searle et al., 2009 ).The functional components of the 77 BiMuno™ mixture are the GOS which are believed not only to stimulate the growth of 78 probiotic bacteria, but may also be able to interact directly with the subject's immune system.
79
This latter possibility has been touted due to studies in murine BALB/c macrophage models 
92
The production of an encapsulated synbiotic has several different challenges compared to the 93 formulation of the probiotic alone. One particular advantage of encapsulating GOS, compared 94 to probiotic cells, is that relatively harsh processing conditions during the encapsulation step 95 may be used. However, for a synbiotic containing GOS and probiotic cells, careful 96 consideration must be taken in order to ensure the applicability of the system to both . In this paper, a multiparticulate microencapsulation system was devised to offer 106 controlled release to GOS, and protection of B. breve to acid. This consisted of individually 107 microencapsulated BiMuno™, which was then incorporated into a chitosan-coated alginate gel 108 containing B. breve, a model probiotic strain. The GOS was encapsulated into a separate 109 system which offers a time-dependent release of small molecules, as the alginate 110 microencapsulation system is too porous to contain the GOS contained in BiMuno™.
111
Poly(D,L-Lactic-co-Glycolic acid) (PLGA) was identified as a plausible material for the time- chains into lactic and glycolic acid, both of which are easily metabolised in the body.
118
There have been a number of multiparticulate dosage forms reported in the literature for the 119 targeting of drugs to the intestine. Eudragit-coated PLGA particles containing budesonide have 120 been fabricated by Krishnamachari et al (Krishnamachari et al., 2007) . These particles were 121 intended to deliver the encapsulated drug to the colon, and showed impressive steady release 122 of drug over 25 hours. There has also been a study of alginate-PLGA multiparticulates for the 
130
It should be noted that diarrhoea is common in bowel disorders, which may lead to 131 premature clearing of microparticles. It has been found that clearing due to diarrhoea is size-132 dependent and that particles of less than 200 microns are retained more effectively during 133 diarrhoea, thus, it is important that microparticles are produced with diameters lower than 134 this threshold (Lamprecht et al., 2004) .
135
This work aimed to develop a multiparticulate system to encapsulate a synbiotic combination 136 of GOS and B.breve. The development of PLGA-GOS microcapsules will be discussed, followed 137 by characterisation of particle size and morphology using microscopy. The release of GOS from 138 these particles in simulated GI conditions was then evaluated and the system expanded to a 139 multiparticulate containing probiotic cells, with associated cell and GOS release data. 
Production of PLGA microcapsules containing GOS
157
The microencapsulation of GOS was attempted by a solvent evaporation technique (Herrmann 158 and Bodmeier, 1995). To form the WOW emulsion, 0.5 mL aqueous BiMuno™ solution of a (Fig 1s, Supporting information) . However, this HPLC technique was very sensitive to capsules, the hardened sample was placed into chitosan solution for 10 min to allow coating of 225 the samples. The capsules were then dried by fluid-bed drying for 15 min at 30°C, with an 226 airflow at 50 % power. To evaluate the release of GOS from these particles, the in vitro GI 227 passage previously described was used. However, the study was halted before the final section 228 (pH 5.5) due to the complete dissolution of the microcapsules. Samples (10 mL) were adjusted to pH 7-7.5, with a measured volume of NaOH (1 M). To these 234 samples 10 mL CaCl 2 (0.05 M) was added, at which point the solutions became cloudy due to The previously evaluated GOS/PLGA microcapsules were prepared as before and placed into 242 10 mL alginate solution (2 % w/v) with stirring before extrusion into 500 mL CaCl 2 solution 243 (0.05 M) with a syringe and pump (2 mL/min). These multiparticulate capsules were allowed to shortened to 72 h, due to the likelihood of excretion in vivo by this point. Additionally, due to 249 the larger sample size, volumes of simulated GI solutions used were multiplied ten-fold. The effect of BiMuno™ concentration on the average particle size and distribution was 295 determined by light microscopy and subsequent image analysis using ImageJ. This data, shown phase may affect the encapsulation efficiency of the system (Mao et al, 2007) , and may be a 309 factor which could be optimised in terms of encapsulation efficiency, as well as particle size. The release of GOS from these GOS/PLGA microcapsules under in vitro GI conditions was 317 measured by ion-exchange HPLC. These studies were initially conducted over a lengthy time phase of release (0-6 h) was likely caused by the diffusion of GOS through pores or the 321 polymer itself. This was followed by a second phase of very little release (6-24 h) at which 322 point the GOS able to diffuse had diminished and the PLGA chains were slowly hydrolysing.
310
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The third phase of release (24-288 h) was the result of the erosion of the particles as the 324 molecular weight of PLGA reduced to such a degree that it became water-soluble. This of the GOS in this case, which is reflected in the low concentration seen in the release data.
373
The microcapsules containing 1.0 mL internal phase were taken forward for further analysis To establish the effect of the polysaccharides alone, alginate and alginate-chitosan 414 microcapsules were loaded with GOS and fluid-bed dried before being put through the 415 simulated GI passage. The rate of GOS release with time was established using the previously 416 described method of purification (Fig. 3s, Supplementary Information) 
433
GOS/PLGA multiparticulates were put through the in vitro GI model previously described and
434
GOS release evaluated using the new purification method. The results in Figure 6 show that 
